Gurit's Wind Turbine Blade Technology European Patent Beats Appeal

Gurit's (SIX Swiss Exchange: GUR) European patent EP 1 128 958, which covers its SPRINT product used mainly in the manufacture of wind turbine blades but also many other Gurit target market applications, was today upheld by the Technical Board of Appeal of the European Patent Office. In reaching this conclusion, the Technical Board of Appeal rejected Hexcel's (NYSE: HXL) opposition to the patent.

Gurit, a leading developer and manufacturer of advanced composite materials and technologies (SIX Swiss Exchange: GUR), announced today that its patent EP 1 128 958, covering Gurit's Sprint product which is mainly used in the manufacture of wind turbine blades but also in many other target market applications of Gurit, was today upheld by the Technical Board of Appeal of the European Patent Office. Although one of the subsidiary claims was deleted, the main claim of the patent was upheld as granted.

In reaching this conclusion, the Technical Board of Appeal rejected Hexcel's opposition to the patent. Hexcel had appealed the earlier Opposition Division decision of January 2008 to uphold the patent. Gurit is pleased that this innovation has been recognized and tested at the highest level of the European Patent office.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Hexcel. (2019, February 10). Gurit's Wind Turbine Blade Technology European Patent Beats Appeal. AZoM. Retrieved on June 23, 2024 from https://www.azom.com/news.aspx?newsID=19594.

  • MLA

    Hexcel. "Gurit's Wind Turbine Blade Technology European Patent Beats Appeal". AZoM. 23 June 2024. <https://www.azom.com/news.aspx?newsID=19594>.

  • Chicago

    Hexcel. "Gurit's Wind Turbine Blade Technology European Patent Beats Appeal". AZoM. https://www.azom.com/news.aspx?newsID=19594. (accessed June 23, 2024).

  • Harvard

    Hexcel. 2019. Gurit's Wind Turbine Blade Technology European Patent Beats Appeal. AZoM, viewed 23 June 2024, https://www.azom.com/news.aspx?newsID=19594.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.